华润医药(03320.HK)治疗孕妇子宫出血药物通过国家药监局一致性评价

阿斯达克财经08-14 12:20

华润医药(03320.HK) 公布，旗下南京新百药业收到中国国家药品监督管理局核准签发的卡前列素氨丁三醇注射液《药品注册证书》，并视同通过一致性评价。
据悉，卡前列素氨丁三醇注射液适用于妊娠期为13至20周的流产，以及与中期流产有关的情况，同时适用于常规处理方法无效的子宫收缩弛缓引起的产后出血现象。

公告亦披露，卡前列素氨丁三醇注射液2021至2023年国内销售额，分别为5.28亿、5.28亿及4.96亿元人民币。(js/k)
(港股报价延迟最少十五分钟。沽空资料截至 2024-08-13 16:25。)

AASTOCKS新闻

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2459192588?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210624132643319_s.jpg","is_english":false,"pubTime":"2024-08-14 12:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2459192588","market":"fut","top_or_hot":-1,"title":"华润医药(03320.HK)治疗孕妇子宫出血药物通过国家药监局一致性评价","media":"阿斯达克财经","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/03320\">华润医药</a>(03320.HK)<span> </span>公布，旗下<a href=\"https://laohu8.com/S/600682\">南京新百</a>药业收到中国国家药品监督管理局核准签发的卡前列素氨丁三醇注射液《药品注册证书》，并视同通过一致性评价。<br/>据悉，卡前列素氨丁三醇注射液适用于妊娠期为13至20周的流产，以及与中期流产有关的情况，同时适用于常规处理方法无效的子宫收缩弛缓引起的产后出血现象。<br/><span></span><br/>公告亦披露，卡前列素氨丁三醇注射液2021至2023年国内销售额，分别为5.28亿、5.28亿及4.96亿元人民币。(js/k)<br/>(港股报价延迟最少十五分钟。沽空资料截至 2024-08-13 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华润医药(03320.HK)治疗孕妇子宫出血药物通过国家药监局一致性评价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华润医药(03320.HK)治疗孕妇子宫出血药物通过国家药监局一致性评价\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯达克财经</strong><span class=\"h-time small\">2024-08-14 12:20</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div> <span> <p><a href=\"https://laohu8.com/S/03320\">华润医药</a>(03320.HK)<span> </span>公布，旗下<a href=\"https://laohu8.com/S/600682\">南京新百</a>药业收到中国国家药品监督管理局核准签发的卡前列素氨丁三醇注射液《药品注册证书》，并视同通过一致性评价。<br/>据悉，卡前列素氨丁三醇注射液适用于妊娠期为13至20周的流产，以及与中期流产有关的情况，同时适用于常规处理方法无效的子宫收缩弛缓引起的产后出血现象。<br/><span></span><br/>公告亦披露，卡前列素氨丁三醇注射液2021至2023年国内销售额，分别为5.28亿、5.28亿及4.96亿元人民币。(js/k)<br/>(港股报价延迟最少十五分钟。沽空资料截至 2024-08-13 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1371478/latest-news/AAFN\">阿斯达克财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1570","symbol_name":"华润系","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1371478/latest-news/AAFN","article_id":"2459192588","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210624132643319_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459192588","pubTimestamp":1723609200,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"华润医药(03320.HK) 公布，旗下南京新百药业收到中国国家药品监督管理局核准签发的卡前列素氨丁三醇注射液《药品注册证书》，并视同通过一致性评价。据悉，卡前列素氨丁三醇注射液适用于妊娠期为13至20周的流产，以及与中期流产有关的情况，同时适用于常规处理方法无效的子宫收缩弛缓引起的产后出血现象。公告亦披露，卡前列素氨丁三醇注射液2021至2023年国内销售额，分别为5.28亿、5.28亿及4.96亿元人民币。(js/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-13 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1570":"华润系","BK1191":"制药","03320":"华润医药"},"translate_title":"China Resources Pharmaceutical (03320. HK) 's drug for treating uterine bleeding in pregnant women passed the consistency evaluation of the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"华润医药(03320.HK) 公布，旗下南京新百药业收到中国国家药品监督管理局核准签发的卡前列素氨丁三醇注射液《药品注册证书》，并视同通过一致性评价。据悉，卡前列素氨丁三醇注射液适用于妊娠期为13至20周的流产，以及与中期流产有关的情况，同时适用于常规处理方法无效的子宫收缩弛缓引起的产后出血现象。公告亦披露，卡前列素氨丁三醇注射液2021至2023年国内销售额，分别为5.28亿、5.28亿及4.96亿元人民币。(js/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-13 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459192588"}